pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 27 Non-oncology: 16
Oncology: 11
Under Consideration for Negotiation 23 Non-oncology: 12
Oncology: 11
Completed Negotiations 892 With Letter of Intent: 772
Without agreement: 120
Negotiations That Were Not Pursued 114

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Talvey Janssen Inc. For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrat
Upgolyv Jamp Pharma Corporation allergic asthma for the treatment of moderate to severe persistent asthma in adult and pediatric patients (6 years of age and above) who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately contr
Talzenna Pfizer Canada ULC ​In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Movantik Knight Therapeutics Inc. Treatment of opioid-induced constipation (OIC) in adult patients with cancer and non-cancer pain who have had an inadequate response to laxative(s).
Opdivo-Yervoy Bristol Myers Squibb Canada Inc. For the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Rybrevant Janssen Inc. In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR)
Rybrevant Janssen Inc. In combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, who
Darzalex SC Janssen Inc. in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Lazcluze and Rybrevant Janssen Inc. For the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Tysabri Biogen Canada Inc. Multiple Sclerosis, Relapsing-Remitting
Signifor LAR Recordati Rare Diseases Canada Inc. Acromegaly in Adults
Penthrox Knight Therapeutics Inc. Adult patients undergoing minor gynecological, ambulatory, or emergency procedures

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks